Articles tagged "Viral therapy"

2022 American Transplant Congress
Hepatitis C Positive Kidney Transplant Into Hepatitis C Negative Recipients
R. Savilla¹, A. Ricketts¹, S. A. Deslich², S. Vaishnav¹, J. B. Africa¹, S. Nagaraju¹
¹Renal Transplant, Charleston Area Medical Center, Charleston, WV, ²Research Associate Senior, Health Services & Outcomes Rsc, Charleston Area Medical Center, Charleston, WV
*Purpose: Kidney transplantation is the treatment of choice in end stage renal disease (ESRD). In 2018, 5% to 8% of eligible adults died while on…
2022 American Transplant Congress
Use of Kidneys from Hepatitis C Nat Positive Donors for Uninfected Recipients: Early Results from a Rural Appalachian Kidney Transplant Program
B. Gillis¹, F. Afridi¹, R. Lopez¹, V. Chaudhary¹, D. Kannabhiran¹, C. Fagella¹, R. Zomak¹, K. Meyer¹, M. Thornberg¹, L. Biondi²
¹Department of Surgery, West Virginia University, Morgantown, WV, ²Department of Surgery, West Virginia University, Morgantown, WV, WV
*Purpose: Increasing mismatch between kidneys available for transplant and the number of patients on the transplant wait list has led to research into novel sources…
2022 American Transplant Congress
A Randomized Phase 2 Study Of Mau868 Vs Placebo To Treat Bk Viremia In Kidney Transplant Recipients
S. Jordan¹, A. P. Limaye², B. Fischbach³, P. Sood⁴, S. Collette⁵, L. Gasink⁶, M. W. Fordyce⁷, C. J. Lin⁷, M. Hodges⁶, D. C. Brennan⁸
¹Cedars-Sinai Medical Center, Los Angeles, CA, ²University of Washington, Seattle, WA, ³Dallas Nephrology Associates, Inc, Dallas, TX, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada, ⁶previous employee/consultant for Amplyx Pharmaceuticals, San Diego, CA, ⁷Vera Therapeutics, Inc, Brisbane, CA, ⁸Johns Hopkins School of Medicine, Baltimore, MD
*Purpose: To assess the safety and efficacy of MAU868, a BK virus-specific monoclonal antibody, in adult kidney transplant recipients with BK viremia.*Methods: This is a…
2022 American Transplant Congress
Risk for Loss of Hepatitis B Surface Antibody or Hepatitis B Reactivation in Kidney Transplant Recipients Receiving Lymphocyte Depleting Induction
K. Paplaczyk¹, C. Kane¹, M. Kapugi¹, K. Lang¹, K. Cunningham¹, C. D'Agostino¹, J. Boike²
¹Pharmacy, Northwestern Memorial Hospital, Chicago, IL, ²Transplant Hepatology, Northwestern Memorial Hospital, Chicago, IL
*Purpose: Although used in over 60% of kidney transplant recipients, the impact of lymphocyte depleting induction on hepatitis B surface antibody (HBsAb) and hepatitis B…
2022 American Transplant Congress
Clinical Features and Outcomes of Hospitalized Solid Organ Transplant and Hematopoietic Stem Cell Recipients with Sars-CoV-2 Infection in the Midwestern United States: A Multi-Center Retrospective Cohort Study
S. Tanna¹, D. Florescu², A. Majeed³, J. Banzon³, S. Waller⁴, A. Eid⁴, N. Barros Baertl⁵, D. Friedman⁶, K. Mullane⁷, M. Ison⁸
¹Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, ²University of Nebraska Medical Center, Omaha, NE, ³Cleveland Clinic, Cleveland, OH, ⁴University of Kansas Medical Center, Overland Park, KS, ⁵Infectious Diseases, Indiana University, Indianapolis, IN, ⁶Infectious Diseases, University of Chicago, Chicago, IL, ⁷University of Chicago, Chicago, IL, ⁸Northwestern University Comprehensive Transplant Center, Chicago, IL
*Purpose: Immunocompromised hosts are at risk for severe complications or death from SARS-CoV-2 infection. Few studies describe the clinical features, outcomes and treatment strategies in…
2022 American Transplant Congress
Letermovir for Prophylaxis of Cytomegalovirus After Solid Organ Transplantation: A Single-Center, Observational Study
T. N. Bullard¹, C. A. Moore², J. Dasigi², L. M. Sacha², C. A. Iasella³, K. A. Shimko², E. K. McCreary⁴, F. P. Silveira⁴
¹Massachusetts General Hospital, Boston, MA, ²UPMC, Pittsburgh, PA, ³Univ of Pittsburgh, Pittsburgh, PA, ⁴Univ of Pittsburgh and UPMC, Pittsburgh, PA
*Purpose: Cytomegalovirus (CMV) infections cause significant complications post-transplant; however, prophylactic medications are often limited by toxicities. Letermovir is a novel terminase inhibitor specific to CMV…
2022 American Transplant Congress
Post-Kidney Transplant Valacyclovir versus Valganciclovir for CMV Prophylaxis: A Randomized Controlled Trial
P. S. Verghese¹, A. Matas², S. Chinnakotla², M. Evans³, H. Balfour Jr⁴
¹Univ of Minnesota Pediatric Nephrology, Minneapolis, MN, ²Surgery, University of Minnesota Medical School, Minneapolis, MN, ³Biostatistics, University of Minnesota, Minneapolis, MN, ⁴Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN
*Purpose: Valganciclovir (valG) is an effective CMV prophylactic agent post-kidney transplant (KTx) with significant side effects. Valacyclovir (valA) may be effective for CMV prophylaxis with…
2022 American Transplant Congress
Use of Viral Specific T Cell Therapy in Solid Organ Transplant Recipients – A Single Center Experience
G. McGraw¹, N. Patel², K. Patel¹, S. Bumb³, A. Govil⁴, M. Anand¹
¹University of Cincinnati, Cincinnati, OH, ²Nephrology, University of Cincinnati, Cincinnati, OH, ³Nephrology, Internal Medicine, University of Cincinnati Medical Center, Blue Ash, OH, ⁴Univ of Cincinnati, Cincinnati, OH
*Purpose: Viral infections such as BK virus (BKV), cytomegalovirus (CMV) and adenovirus after kidney transplantation negatively impact outcomes in solid organ transplant (SOT) recipients despite…
2022 American Transplant Congress
Impact of Glecaprevir/Pibrentasvir on Tacrolimus Concentration in Solid Organ Transplant Recipients with or without Triazole Antifungal Therapy
D. Abraham¹, A. Feist², N. Law¹, S. Aslam¹, V. Nguyen¹
¹University of California San Diego Health, San Diego, CA, ²University of California San Diego, San Diego, CA
*Purpose: Provide guidance on tacrolimus (TAC) dose adjustments during glecaprevir/pibrentasvir (GLE/PIB) initiation and discontinuation in patients on triazole antifungals by comparing changes in TAC concentration-dose…
2022 American Transplant Congress
The Prevalence And Risk Factors Of De Novo Hepatitis B Virus Infection In Kidney Transplantation From Hepatitis B Antigen-positive Donors To Hbsag-negative Recipients
J. Wu¹, S. Yin¹, F. Zhang¹, L. Wu¹, X. Wang², T. Lin¹
¹urology, west china hospital, Chengdu, China, ²Urology, West China Hospital, Chengdu, China
*Purpose: To explore the prevalence and risk factors of de novo HBV infection (DNH) in kidney transplantation (KT) from HBsAg⁺ donors (D[HBsAg⁺]) to HBsAg-negative recipients…